Kerala Ayurveda Limited (KERALAYUR) Share Price
BSE · Healthcare · Drug Manufacturers - Specialty & Generic · ISIN INE817B01025
Key metrics
- Market Cap
- ₹246 Cr
- P/E Ratio
- —
- EPS
- -21.68
- Book Value
- 11.46
- P/B Ratio
- 16.5
- ROE
- -111.2%
- ROCE
- -22.92%
- Debt / Equity
- 5.81
- Net Margin
- -12.62%
- Revenue Growth
- 8.99%
- Profit Growth
- -12.64%
- Dividend Yield
- —
- 52W High
- ₹506.85
- 52W Low
- ₹145.00
- Market Cap Band
- micro cap
- Face Value
- —
Ratios computed from the annual results period ending 2026-03-31.
About Kerala Ayurveda Limited
Kerala Ayurveda Limited manufactures and sells ayurvedic products in India. It offers classical and proprietary ayurvedic medicines, including therapeutic formulations, as well as health supplements, skin and beauty care products, and specialty foods. The company's products include pain relief, joint and muscle care, women and men health, immunity and general wellness, stress management and brain health, skin, hair and personal care, metabolism and gut health, child care and teen health, and geriatric care. It provides wellness centers and clinics, hospitals, health village, wellness resort, and yoga therapy services, as well as academies. The company was founded in 1945 and is headquartered in Aluva, India. Kerala Ayurveda Limited operates as a subsidiary of Katra Holdings Limited.
- Headquarters
- Aluva, India
- Promoter Holding
- 59.43%
The full Kerala Ayurveda Limited analysis
Create a free account to open the complete KERALAYUR deep-dive — fourteen tabs of fundamental, technical, institutional and ownership data.
- 10-year financialsIncome statement, balance sheet and cash flow, year by year.
- Valuation & fair valueFair-value estimates, quality scores and a value grade.
- Charts & technicalsCandlestick charts, RSI, MACD, Supertrend and detected patterns.
- Shareholding historyPromoter, FII, DII and public holdings across every quarter.
- Ace investor holdingsWhich well-known investors hold it, and how their stake changed.
- Deals & insider tradesBulk and block deals, insider transactions and mutual-fund holdings.